Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Could widespread use of combination antiretroviral therapy eradicate HIV epidemics?

Velasco-Hernandez JX, Gershengorn HB, Blower SM.

Lancet Infect Dis. 2002 Aug;2(8):487-93. Review.

PMID:
12150848
2.

Evolutionary dynamics of complex networks of HIV drug-resistant strains: the case of San Francisco.

Smith RJ, Okano JT, Kahn JS, Bodine EN, Blower S.

Science. 2010 Feb 5;327(5966):697-701. doi: 10.1126/science.1180556. Epub 2010 Jan 14.

3.

A resurgent HIV-1 epidemic among men who have sex with men in the era of potent antiretroviral therapy.

Bezemer D, de Wolf F, Boerlijst MC, van Sighem A, Hollingsworth TD, Prins M, Geskus RB, Gras L, Coutinho RA, Fraser C.

AIDS. 2008 May 31;22(9):1071-7. doi: 10.1097/QAD.0b013e3282fd167c.

PMID:
18520351
4.

Forecasting the future of HIV epidemics: the impact of antiretroviral therapies & imperfect vaccines.

Blower S, Schwartz EJ, Mills J.

AIDS Rev. 2003 Apr-Jun;5(2):113-25. Review.

PMID:
12876900
5.

Association between risk behaviors and antiretroviral resistance in HIV-infected patients receiving opioid agonist treatment.

Tetrault JM, Kozal MJ, Chiarella J, Sullivan LE, Dinh AT, Fiellin DA.

J Addict Med. 2013 Mar-Apr;7(2):102-7. doi: 10.1097/ADM.0b013e31827f9bdf.

6.

A tale of two futures: HIV and antiretroviral therapy in San Francisco.

Blower SM, Gershengorn HB, Grant RM.

Science. 2000 Jan 28;287(5453):650-4.

7.

Modeling trends in HIV incidence among homosexual men in Australia 1995-2006.

Clements MS, Prestage G, Grulich A, Van de Ven P, Kippax S, Law MG.

J Acquir Immune Defic Syndr. 2004 Apr 1;35(4):401-6.

PMID:
15097157
8.

Predicting the impact of antiretrovirals in resource-poor settings: preventing HIV infections whilst controlling drug resistance.

Blower S, Ma L, Farmer P, Koenig S.

Curr Drug Targets Infect Disord. 2003 Dec;3(4):345-53. Review.

PMID:
14754434
9.

Modeling and analysis of the San Francisco City Clinic Cohort (SFCCC) HIV-epidemic including treatment.

Rapatski B, Tolosa J.

Math Biosci Eng. 2014 Jun;11(3):599-619. doi: 10.3934/mbe.2014.11.599.

PMID:
24506553
10.

A decrease in drug resistance levels of the HIV epidemic can be bad news.

Sánchez MS, Grant RM, Porco TC, Gross KL, Getz WM.

Bull Math Biol. 2005 Jul;67(4):761-82. Epub 2004 Dec 15.

11.

Treatment for prevention of HIV transmission in a localised epidemic: the case for South Australia.

Heymer KJ, Wilson DP.

Sex Health. 2011 Sep;8(3):280-94. doi: 10.1071/SH10084.

PMID:
21851767
14.

The antiretroviral rollout and drug-resistant HIV in Africa: insights from empirical data and theoretical models.

Blower S, Bodine E, Kahn J, McFarland W.

AIDS. 2005 Jan 3;19(1):1-14. Review.

PMID:
15627028
15.
16.

Modelling the impact of HIV prevention and treatment for men who have sex with men on HIV epidemic trajectories in low- and middle-income countries.

Wirtz AL, Walker DG, Bollinger L, Sifakis F, Baral S, Johns B, Oelrichs R, Beyrer C.

Int J STD AIDS. 2013 Jan;24(1):18-30. doi: 10.1177/0956462412472291. Epub 2013 May 6.

PMID:
23512511
17.

The HIV/AIDS epidemic in Cuba: description and tentative explanation of its low HIV prevalence.

de Arazoza H, Joanes J, Lounes R, Legeai C, Clémençon S, Pérez J, Auvert B.

BMC Infect Dis. 2007 Nov 9;7:130.

18.

High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lomé, Togo.

Dagnra AY, Vidal N, Mensah A, Patassi A, Aho K, Salou M, Monleau M, Prince-David M, Singo A, Pitche P, Delaporte E, Peeters M.

J Int AIDS Soc. 2011 Jun 10;14:30. doi: 10.1186/1758-2652-14-30.

19.

High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Côte d'Ivoire.

Adjé C, Cheingsong R, Roels TH, Maurice C, Djomand G, Verbiest W, Hertogs K, Larder B, Monga B, Peeters M, Eholie S, Bissagene E, Coulibaly M, Respess R, Wiktor SZ, Chorba T, Nkengasong JN; UNAIDS HIV Drug Access Initiative, Abidjan, Côte d'Ivoire..

J Acquir Immune Defic Syndr. 2001 Apr 15;26(5):501-6.

PMID:
11391173
20.

Modeling HIV vaccines in Brazil: assessing the impact of a future HIV vaccine on reducing new infections, mortality and number of people receiving ARV.

Fonseca MG, Forsythe S, Menezes A, Vuthoori S, Possas C, Veloso VG, Lucena Fde F, Stover J.

PLoS One. 2010 Jul 23;5(7):e11736. doi: 10.1371/journal.pone.0011736. Erratum in: PLoS One. 2010 Aug 18;5(8) doi: 10.1371/annotation/4fd10061-5a1e-4164-833e-34943a74301c.. Veloso, Valdiléa [corrected to Veloso, Valdiléa Gonçalves].

Supplemental Content

Support Center